从布鲁内克研究和PACMAN-AMI试验中的血小板非编码RNA含量和释放的血小板和炎症见解
Clemens Gutmann1,2, Temo Barwari2, Christian Schulte2,3,4
1Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Cardiovascular research
|June 3, 2025
概括
血小板非编码RNAs (ncRNAs) 提供了一个新的生物标志物,补充了传统的聚合学. 它们的释放是激素特异性的,受炎症的影响,为血小板功能和双重抗血小板治疗效果提供了更深入的见解.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 血小板含有非编码RNA (ncRNA),可以作为生物标志物.
- 血小板聚合计是血小板功能的标准测量方法.
- ncRNAs可能会补充血小板聚合度.
研究的目的:
- 为了研究血小板ncRNAs的释放模式.
- 为了比较ncRNA释放与血小板聚合.
- 探索ncRNAs与炎症和抗血小板治疗的关联.
主要方法:
- 生成的富血小板血 (PRP),贫血小板血 (PPP) 和来自社区研究参与者的血小板 (n=338).
- 进行了血小板聚合计,并使用实时PCR测量了释放物,PPP和血小板中的ncRNA.
- 在急性心肌梗塞 (AMI) 患者中分析了与炎症标志物的关联,并评估了对双抗血小板治疗 (DAPT) 的ncRNA反应 (n=265).
主要成果:
- 血小板的ncRNA释放是激动剂特异的,剂量依赖的,并且被阿司匹林抑制.
- 原诱导了最强的释放,与特定的microRNAs显示过敏对ADP和酸.
- 与聚合不同的是,ncRNA释放继续随着激动剂度的增加而上升.
- 炎症标志物和白细胞衍生的RNA与血小板聚合和ncRNA释放相反相关.
- 与蛋白质结合的ncRNAs (microRNAs,YRNAs) 容易释放,而与囊泡结合的ncRNAs (circRNAs, lncRNAs,mRNAs) 则被保留.
- DAPT显示了对未通过聚合计学捕获的ncRNAs的短期和长期影响.
结论:
- 血小板中的炎症和白细胞衍生的RNA与减少的活体血小板反应有关.
- 蛋白质结合的ncRNAs被释放,而囊泡结合的ncRNAs被血小板保留.
- 血小板ncRNA显示出作为生物标志物的潜力,这些生物标志物补充了评估血小板功能和DAPT疗效的聚合学.
相关概念视频
Structure and Function of Platelets
1.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
656
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656


